These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 30579863)

  • 41. Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice.
    Liu X; Barrett DM; Jiang S; Fang C; Kalos M; Grupp SA; June CH; Zhao Y
    Blood Cancer J; 2016 Jun; 6(6):e430. PubMed ID: 27258611
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
    Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
    Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
    [No Abstract]   [Full Text] [Related]  

  • 43. A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia.
    Enblad G; Karlsson H; Gammelgård G; Wenthe J; Lövgren T; Amini RM; Wikstrom KI; Essand M; Savoldo B; Hallböök H; Höglund M; Dotti G; Brenner MK; Hagberg H; Loskog A
    Clin Cancer Res; 2018 Dec; 24(24):6185-6194. PubMed ID: 30097433
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chimeric Antigen Receptor T Cell Therapy Targeting CD19-Positive Leukemia and Lymphoma in the Context of Stem Cell Transplantation.
    Schubert ML; Hückelhoven A; Hoffmann JM; Schmitt A; Wuchter P; Sellner L; Hofmann S; Ho AD; Dreger P; Schmitt M
    Hum Gene Ther; 2016 Oct; 27(10):758-771. PubMed ID: 27479233
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fully human CD19-specific chimeric antigen receptors for T-cell therapy.
    Sommermeyer D; Hill T; Shamah SM; Salter AI; Chen Y; Mohler KM; Riddell SR
    Leukemia; 2017 Oct; 31(10):2191-2199. PubMed ID: 28202953
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts.
    Bishop DC; Xu N; Tse B; O'Brien TA; Gottlieb DJ; Dolnikov A; Micklethwaite KP
    Mol Ther; 2018 Aug; 26(8):1883-1895. PubMed ID: 29861327
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting Two Antigens Associated with B-ALL with CD19-CD123 Compound Car T Cell Therapy.
    Yan LE; Zhang H; Wada M; Fang L; Feng J; Zhang W; Chen Q; Cao Y; Pinz KG; Chen KH; Petrov JC; Chen X; Leung LH; Fan XX; Senzel L; Jiang X; Ma Y; Tse W
    Stem Cell Rev Rep; 2020 Apr; 16(2):385-396. PubMed ID: 31970687
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
    Ramos CA; Rouce R; Robertson CS; Reyna A; Narala N; Vyas G; Mehta B; Zhang H; Dakhova O; Carrum G; Kamble RT; Gee AP; Mei Z; Wu MF; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Savoldo B; Dotti G
    Mol Ther; 2018 Dec; 26(12):2727-2737. PubMed ID: 30309819
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antigenic targets of CAR T Cell Therapy. A retrospective view on clinical trials.
    Arabi F; Torabi-Rahvar M; Shariati A; Ahmadbeigi N; Naderi M
    Exp Cell Res; 2018 Aug; 369(1):1-10. PubMed ID: 29758187
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antileukemic potency of CD19-specific T cells against chemoresistant pediatric acute lymphoblastic leukemia.
    Dolnikov A; Shen S; Klamer G; Joshi S; Xu N; Yang L; Micklethwaite K; O'Brien TA
    Exp Hematol; 2015 Dec; 43(12):1001-1014.e5. PubMed ID: 26384559
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice.
    Mulazzani M; Fräßle SP; von Mücke-Heim I; Langer S; Zhou X; Ishikawa-Ankerhold H; Leube J; Zhang W; Dötsch S; Svec M; Rudelius M; Dreyling M; von Bergwelt-Baildon M; Straube A; Buchholz VR; Busch DH; von Baumgarten L
    Proc Natl Acad Sci U S A; 2019 Nov; 116(48):24275-24284. PubMed ID: 31712432
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia.
    Weng J; Lai P; Qin L; Lai Y; Jiang Z; Luo C; Huang X; Wu S; Shao D; Deng C; Huang L; Lu Z; Zhou M; Zeng L; Chen D; Wang Y; Chen X; Geng S; Robert W; Tang Z; He C; Li P; Du X
    J Hematol Oncol; 2018 Feb; 11(1):25. PubMed ID: 29458388
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells.
    Singh H; Figliola MJ; Dawson MJ; Olivares S; Zhang L; Yang G; Maiti S; Manuri P; Senyukov V; Jena B; Kebriaei P; Champlin RE; Huls H; Cooper LJ
    PLoS One; 2013; 8(5):e64138. PubMed ID: 23741305
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials.
    Zhu Y; Tan Y; Ou R; Zhong Q; Zheng L; Du Y; Zhang Q; Huang J
    Eur J Haematol; 2016 Apr; 96(4):389-96. PubMed ID: 26115358
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of advanced leukemia in mice with mRNA engineered T cells.
    Barrett DM; Zhao Y; Liu X; Jiang S; Carpenito C; Kalos M; Carroll RG; June CH; Grupp SA
    Hum Gene Ther; 2011 Dec; 22(12):1575-86. PubMed ID: 21838572
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Early recovery of circulating immature B cells in B-lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: A pitfall for minimal residual disease detection.
    Xiao W; Salem D; McCoy CS; Lee D; Shah NN; Stetler-Stevenson M; Yuan CM
    Cytometry B Clin Cytom; 2018 May; 94(3):434-443. PubMed ID: 28888074
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CAR T cells: Building on the CD19 paradigm.
    Globerson Levin A; Rivière I; Eshhar Z; Sadelain M
    Eur J Immunol; 2021 Sep; 51(9):2151-2163. PubMed ID: 34196410
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development and functional characterization of novel fully human anti-CD19 chimeric antigen receptors for T-cell therapy.
    Dai Z; Hu X; Jia X; Liu J; Yang Y; Niu P; Hu G; Tan T; Zhou J
    J Cell Physiol; 2021 Aug; 236(8):5832-5847. PubMed ID: 33432627
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CD19 chimeric antigen receptor T cell therapy in leukemia xenograft mouse: Anti-leukemic efficacy, kinetics, and 4-week single-dose toxicity.
    Kim JI; Park MY; Kwon E; Kang HJ; Kang BC
    Toxicol Appl Pharmacol; 2023 Sep; 475():116628. PubMed ID: 37506978
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line.
    Kang CH; Kim Y; Lee HK; Lee SM; Jeong HG; Choi SU; Park CH
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.